The OS advantage was clearly demonstrable in favorable/intermediate risk BCL-2− AML patients (median OS of BCL-2− vs. BCL-2+ patients: undefined vs. 18.8 months; p = 0.0411; Figure 3A). This evidence concerns the gene BCL2 and acute myeloid leukemia.